Análisis estadístico por regresión lineal de la prevalencia de pie plano en preescolar de una comunidad de México

Context: In Mexico's rural towns, it is essential to generate a culture of studying the prevalence of flat feet in children aged 3 to 5, whose arch is still in development and can be corrected. By means of a computer application, statistical bar graph and correlation studies via linear regression can validate the results obtained regarding the categorization of infants' footprint type, which are acquired through the Hernández Corvo index (HCI), Clarke’s angle protocol (CA), the Staheli index (SI), the Chippaux index (CI), and the body mass index (BMI). Methods: A statistical analysis of the plantar footprint of 95 infants in a rural region of Mexico was carried out, employing a computational technique together with a photo-podoscope. Footprint images were acquired, processed, and classified. The footprint type was categorized with respect to the HCI, CA, and the Staheli-Chippaux index (SCI). The footprint distribution was validated via the linear regression method. Results: We evidenced a prevalence of flat foot of 54,7% in relation to HCI, 58,9% in relation to CA, and 61,05% in relation to SCI, where the male gender was shown to be more susceptible (up to 28, 32, and 33 cases, respectively). The best prediction was obtained using the SI and the CI: 90,7 and 87,0% for the right and left feet, with a positive increase. No dependence on body composition was observed. Conclusions: The diagnosis of the type of footstep, in its normal, cavus, and flat categories, shows the prevalence of flat feet among infants aged 3 to 5, with at least 28 cases, mostly male and without dependence on weight. Although it is difficult to perform plantar footprint diagnoses in the rural communities of Mexico, this statistical study highlights the importance of monitoring foot development in preschool infants with the advantages and practicality of computational techniques.Contexto: En las comunidades de México, es fundamental generar una cultura de estudiar la prevalencia del pie plano en niños de 3 a 5 años, cuyo arco aún está en desarrollo y se puede corregir. Mediante el uso de una aplicación computacional, los estudios estadísticos de gráficos de barras y correlación por medio de regresión lineal validan los resultados sobre la categorización del tipo de pisada del infante, los cuales se adquieren mediante el índice Hernández Corvo (HCI), el protocolo del ángulo de Clarke (CA), el índice Staheli (SI), el índice Chippaux (CI) y el índice de masa corporal (BMI). Método: Se realizó un análisis estadístico de la huella plantar de 95 infantes de una comunidad de México, empleando una técnica computacional junto con un fotopodoscopio. Se adquirió, procesó y clasificó la imagen de la pisada. Se categorizó el tipo de pisada con respecto al HCI, el CA y el índice Staheli-Chippaux (SCI). La distribución de las huellas se validó mediante el método de regresión lineal. Resultados: Se evidenció una prevalencia de pie plano de 54,7 % respecto al HCI, 58,9 % respecto al CA y 61,05 % respecto al SCI, donde el sexo masculino fue el más susceptible (hasta 28, 32 y 33 casos). La mejor predicción se obtuvo mediante el SI y el CI: 90,7 y 87,0% para los pies derecho e izquierdo, con incremento positivo. No se observó dependencia con la composición corporal. Conclusiones: El diagnóstico del tipo de pisada, en sus categorías normal, cavo y plano, evidencia la prevalencia del pie plano entre los infantes de 3 a 5 años, con al menos 28 casos, en su mayoría masculinos y sin dependencia del peso. Si bien es difícil realizar diagnósticos de huella plantar en las comunidades rurales de México, este estudio estadístico muestra la importancia de monitorear el desarrollo del pie en infantes de preescolar, con las ventajas y la practicidad de las técnicas computacionales.

Statistical Analysis by Linear Regression of the Prevalence of Flatfoot in Preschool Children of a Mexican Community

Context: In Mexico's rural towns, it is essential to generate a culture of studying the prevalence of flat feet in children aged 3 to 5, whose arch is still in development and can be corrected. By means of a computer application, statistical bar graph and correlation studies via linear regression can validate the results obtained regarding the categorization of infants' footprint type, which are acquired through the Hernández Corvo index (HCI), Clarke’s angle protocol (CA), the Staheli index (SI), the Chippaux index (CI), and the body mass index (BMI). Methods: A statistical analysis of the plantar footprint of 95 infants in a rural region of Mexico was carried out, employing a computational technique together with a photo-podoscope. Footprint images were acquired, processed, and classified. The footprint type was categorized with respect to the HCI, CA, and the Staheli-Chippaux index (SCI). The footprint distribution was validated via the linear regression method. Results: We evidenced a prevalence of flat foot of 54,7% in relation to HCI, 58,9% in relation to CA, and 61,05% in relation to SCI, where the male gender was shown to be more susceptible (up to 28, 32, and 33 cases, respectively). The best prediction was obtained using the SI and the CI: 90,7 and 87,0% for the right and left feet, with a positive increase. No dependence on body composition was observed. Conclusions: The diagnosis of the type of footstep, in its normal, cavus, and flat categories, shows the prevalence of flat feet among infants aged 3 to 5, with at least 28 cases, mostly male and without dependence on weight. Although it is difficult to perform plantar footprint diagnoses in the rural communities of Mexico, this statistical study highlights the importance of monitoring foot development in preschool infants with the advantages and practicality of computational techniques

Surface Analysis of 4-Aminothiophenol Adsorption at Polycrystalline Platinum Electrodes

Formation of self-assembled monolayer (SAM) of 4-aminothiophenol (4-ATP) on polycrystalline platinum electrodes has been studied by surface analysis and electrochemistry techniques. The 4-ATP monolayer was characterized by cyclic voltammetry (CV), Raman spectroscopy, reflection absorption infrared (RAIR) spectroscopy, and X-ray photoelectron spectroscopy (XPS). Cyclic voltammetry (CV) experiments give an idea about the packing quality of the monolayer. RAIR and Raman spectra for 4-ATP modified platinum electrodes showed the characteristic adsorption bands for neat 4-ATP indicating the adsorption of 4-ATP molecules on platinum surface. The adsorption on platinum was also evidenced by the presence of sulfur and nitrogen peaks by XPS survey spectra of the modified platinum electrodes. High resolution XPS studies and RAIR spectrum for platinum electrodes modified with 4-ATP indicate that molecules are sulfur-bonded to the platinum surface. The formation of S-Pt bond suggests that ATP adsorption gives up an amino terminated SAM. Thickness of the monolayer was evaluated via angle-resolved XPS (AR-XPS) analyses. Derivatization of 4-ATP SAM was performed using 16-Br hexadecanoic acid

Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature

Disease control at 5 years would be a desirable endpoint for elderly multiple myeloma (MM) patients, but biomarkers predicting this are not defined. Therefore, to gain further insights in this endpoint, a population of 498 newly diagnosed transplant-ineligible patients enrolled in two Spanish trials (GEM2005MAS65 and GEM2010MAS65), has been analyzed. Among the 435 patients included in this post-hoc study, 18.6% remained alive and progression free after 5 years of treatment initiation. In these patients, overall survival (OS) rate at 10 years was 60.8% as compared with 11.8% for those progressing within the first 5 years. Hemoglobin (Hb) = 12 g/dl (OR 2.74, p = 0.001) and MGUS-like profile (OR 4.18, p = 0.005) were the two baseline variables associated with long-term disease-free survival. Upon including depth of response (and MRD), Hb = 12 g/dl (OR 2.27) and MGUS-like signature (OR 7.48) retained their predictive value along with MRD negativity (OR 5.18). This study shows that despite the use of novel agents, the probability of disease control at 5 years is still restricted to a small fraction (18.6%) of elderly MM patients. Since this endpoint is associated with higher rates of OS, this study provides important information about diagnostic and post-treatment biomarkers helpful in predicting the likelihood of disease control at 5 years

Search for direct production of charginos and neutralinos in events with three leptons and missing transverse momentum in √s = 7 TeV pp collisions with the ATLAS detector

A search for the direct production of charginos and neutralinos in final states with three electrons or muons and missing transverse momentum is presented. The analysis is based on 4.7 fb−1 of proton–proton collision data delivered by the Large Hadron Collider and recorded with the ATLAS detector. Observations are consistent with Standard Model expectations in three signal regions that are either depleted or enriched in Z-boson decays. Upper limits at 95% confidence level are set in R-parity conserving phenomenological minimal supersymmetric models and in simplified models, significantly extending previous results

In Vitro and In Vivo Efficacy of Ether Lipid Edelfosine against Leishmania spp. and SbV-Resistant Parasites

Leishmaniasis represents a major international health problem, has a high morbidity and mortality rate, and is classified as an emerging and uncontrolled disease by the World Health Organization. The migration of population from endemic to nonendemic areas, and tourist activities in endemic regions are spreading the disease to new areas. Unfortunately, treatment of leishmaniasis is far from satisfactory, with only a few drugs available that show significant side-effects. Here, we show in vitro and in vivo evidence for the antileishmanial activity of the ether phospholipid edelfosine, being effective against a wide number of Leishmania spp. causing cutaneous, mucocutaneous and visceral leishmaniasis. Our experimental mouse and hamster models demonstrated not only a significant antileishmanial activity of edelfosine oral administration against different wild-type Leishmania spp., but also against parasites resistant to pentavalent antimonials, which constitute the first line of treatment worldwide. In addition, edelfosine exerted a higher antileishmanial activity and a lower proneness to generate drug resistance than miltefosine, the first drug against leishmaniasis that can be administered orally. These data, together with our previous findings, showing an anti-inflammatory action and a very low toxicity profile, suggest that edelfosine is a promising orally administered drug for leishmaniasis, thus warranting clinical evaluation

Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

Background: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of differences in patient characteristics and outcomes that may result. Methods and Results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at diagnosis of AF were recruited either retrospectively (n = 5069) or prospectively (n = 5501) from 19 countries and then followed prospectively. The retrospectively enrolled cohort comprised patients with established AF (for a least 6, and up to 24 months before enrolment), who were identified retrospectively (and baseline and partial follow-up data were collected from the emedical records) and then followed prospectively between 0-18 months (such that the total time of follow-up was 24 months; data collection Dec-2009 and Oct-2010). In the prospectively enrolled cohort, patients with newly diagnosed AF (≤6 weeks after diagnosis) were recruited between Mar-2010 and Oct-2011 and were followed for 24 months after enrolment. Differences between the cohorts were observed in clinical characteristics, including type of AF, stroke prevention strategies, and event rates. More patients in the retrospectively identified cohort received vitamin K antagonists (62.1% vs. 53.2%) and fewer received non-vitamin K oral anticoagulants (1.8% vs . 4.2%). All-cause mortality rates per 100 person-years during the prospective follow-up (starting the first study visit up to 1 year) were significantly lower in the retrospective than prospectively identified cohort (3.04 [95% CI 2.51 to 3.67] vs . 4.05 [95% CI 3.53 to 4.63]; p = 0.016). Conclusions: Interpretations of data from registries that aim to evaluate the characteristics and outcomes of patients with AF must take account of differences in registry design and the impact of recall bias and survivorship bias that is incurred with retrospective enrolment. Clinical Trial Registration: - URL: http://www.clinicaltrials.gov . Unique identifier for GARFIELD-AF (NCT01090362)

Search for direct top squark pair production in events with a Z boson, b-jets and missing transverse momentum in s √ = 8 TeV pp collisions with the ATLAS detector

A search is presented for direct top squark pair production using events with at least two leptons including a same-flavour opposite-sign pair with invariant mass consistent with the Z boson mass, jets tagged as originating from b-quarks and missing transverse momentum. The analysis is performed with proton–proton collision data at s√=8 TeV collected with the ATLAS detector at the LHC in 2012 corresponding to an integrated luminosity of 20.3 fb−¹. No excess beyond the Standard Model expectation is observed. Interpretations of the results are provided in models based on the direct pair production of the heavier top squark state (t~2) followed by the decay to the lighter top squark state (t~1) via t~2→Zt~1, and for t~1 pair production in natural gauge-mediated supersymmetry breaking scenarios where the neutralino (χ~10) is the next-to-lightest supersymmetric particle and decays producing a Z boson and a gravitino (G~) via the χ~10→ZG~ process

Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation. the GLORIA-AF registry

Aim: The SAMe-TT2R2 score helps identify patients with atrial fibrillation (AF) likely to have poor anticoagulation control during anticoagulation with vitamin K antagonists (VKA) and those with scores >2 might be better managed with a target-specific oral anticoagulant (NOAC). We hypothesized that in clinical practice, VKAs may be prescribed less frequently to patients with AF and SAMe-TT2R2 scores >2 than to patients with lower scores. Methods and results: We analyzed the Phase III dataset of the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF), a large, global, prospective global registry of patients with newly diagnosed AF and ≥1 stroke risk factor. We compared baseline clinical characteristics and antithrombotic prescriptions to determine the probability of the VKA prescription among anticoagulated patients with the baseline SAMe-TT2R2 score >2 and ≤ 2. Among 17,465 anticoagulated patients with AF, 4,828 (27.6%) patients were prescribed VKA and 12,637 (72.4%) patients an NOAC: 11,884 (68.0%) patients had SAMe-TT2R2 scores 0-2 and 5,581 (32.0%) patients had scores >2. The proportion of patients prescribed VKA was 28.0% among patients with SAMe-TT2R2 scores >2 and 27.5% in those with scores ≤2. Conclusions: The lack of a clear association between the SAMe-TT2R2 score and anticoagulant selection may be attributed to the relative efficacy and safety profiles between NOACs and VKAs as well as to the absence of trial evidence that an SAMe-TT2R2-guided strategy for the selection of the type of anticoagulation in NVAF patients has an impact on clinical outcomes of efficacy and safety. The latter hypothesis is currently being tested in a randomized controlled trial. Clinical trial registration: URL: https://www.clinicaltrials.gov//Unique identifier: NCT01937377, NCT01468701, and NCT01671007